You're assuming the reason for US costs being so high is R&D, and then asking me to prove it's not.
US market share of R&D spending in health is dropping pretty consistently, whilst still leaving them leaders. In your estimation, shouldn't this have a relative impact on affordability? And yet revenue per dollar spend on R&D sits at just over 700% in the US. Don't you think an unregulated market may be contributing to this?
It's a tricky topic, and I don't mean to sound like I'm tossing out your thoughts here. I suspect elements of what you say does contribute. But I remain mystified why this isn't a larger discussion point in the US, and why the belief that 'other countries aren't paying their share' is actually viewed as a way to close out the discussion.
I wish China paid more for Australian metal. It would boost our national economy. Although it would also drive up inflation. Ultimately, though, the price China pays for our minerals, and the long term viability of the market are key discussion points here, alongside the recognition that there are only certain things we can control. I would hazard a guess that there is plenty the US can do to reduce their per capita spend on healthcare, or improve the quality of care...or both. What is lacking isn't foreign countries willing to pay more for US drugs, or R&D.
Does Expensive American Healthcare Fund R&D and Medical Research? (mhaonline.com)